The company is currently in Phase II testing of ZYN002 for treatment of refractory epilepsy and osteoarthritis. It’s also in Phase I testing of ZYN002 for treatment of Fragile X syndrome. ZYN001 is still in preclinical testing for multiple indications as well.
Shares of ZYNE stumbled at the start of 2017 as the company announced a 2.8 million-share offering ...